Splicing factor mutant myelodysplastic syndromes: Recent advances

Area of Science:

• Molecular Biology
• Hematology
• Oncology

Background:

• Myelodysplastic syndromes (MDS) are myeloid malignancies that can progress to acute myeloid leukemia (AML).
• Mutations in splicing factor genes are prevalent in MDS, affecting over 50% of patients.
• Aberrant pre-mRNA splicing due to spliceosome dysfunction is implicated in MDS pathogenesis.

Purpose of the Study:

• To investigate the role of aberrant spliceosome function in MDS and AML.
• To explore the impact of splicing factor mutations on gene expression and cellular signaling pathways.
• To evaluate the therapeutic potential of spliceosome inhibitors in splicing factor mutant MDS and AML.

Main Methods:

• Analysis of splicing factor gene mutations in MDS and AML patient samples.
• Functional studies on the impact of aberrant splicing on hematopoiesis and signaling pathways.
• Pre-clinical evaluation of spliceosome inhibitors (e.g., E7107, H3B-8800) in relevant models.

Main Results:

• Splicing factor mutations lead to aberrant splicing of target genes, affecting NF-κB signaling and causing R-loop elevation and DNA damage.
• Aberrantly spliced genes impact hematopoietic stem cell function.
• Pre-clinical data suggest spliceosome inhibitors are effective against splicing factor mutant MDS and AML cells.

Conclusions:

• Aberrant spliceosome function is a key driver of MDS and AML.
• Targeting spliceosome function with inhibitors offers a promising therapeutic strategy for splicing factor mutant MDS and AML.
• Understanding the molecular mechanisms of splicing factor mutations provides novel insights into disease pathophysiology.